CiMaas develops immunotherapy for cancer by optimally engaging the immune system.
Mr Alexander Vos joined the Supervisory Board of CiMaas in May 2018. Alexander Vos is the former CEO of PharmaCell BV, based in Maastricht and Geleen.
CiMaas announced the granting of a European Patent on its Dendritic Cells maturation technology, an essential part of its Dendritic Cell Vaccine Product.
CiMaas moves it's clinical production site to InSciTe in Sittard-Geleen. Working together in the Biomedical Accelerator Matrix, CiMaas and InSciTe are joining forces to bring a cure for cancer one step closer to reality.